Abbott Laboratories (ABT)vsClearpoint Neuro Inc (CLPT)
ABT
Abbott Laboratories
$105.62
-2.21%
HEALTHCARE · Cap: $177.07B
CLPT
Clearpoint Neuro Inc
$14.14
-2.68%
HEALTHCARE · Cap: $450.74M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 114602% more annual revenue ($46.59B vs $40.61M). ABT leads profitability with a 11.7% profit margin vs -71.6%. CLPT appears more attractively valued with a PEG of 0.61. ABT earns a higher WallStSmart Score of 52/100 (C-).
ABT
Buy52
out of 100
Grade: C-
CLPT
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-46.2%
Fair Value
$73.35
Current Price
$105.62
$32.27 premium
Margin of Safety
+10.2%
Fair Value
$14.88
Current Price
$14.14
$0.74 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Revenue surging 42.9% year-over-year
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 22.4x book value
ROE of -154.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : CLPT
The strongest argument for CLPT centers on Revenue Growth, PEG Ratio. Revenue growth of 42.9% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : CLPT
The primary concerns for CLPT are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 3.37 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABT profiles as a value stock while CLPT is a hypergrowth play — different risk/reward profiles.
CLPT carries more volatility with a beta of 1.24 — expect wider price swings.
CLPT is growing revenue faster at 42.9% — sustainability is the question.
ABT generates stronger free cash flow (916M), providing more financial flexibility.
Bottom Line
ABT scores higher overall (52/100 vs 37/100) and 13.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Clearpoint Neuro Inc
HEALTHCARE · MEDICAL DEVICES · USA
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?